Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04220190 · ClinicalTrials.gov registry record · Phase 2
RAPA-501 Therapy for ALS
A Phase 2 study of Amyotrophic Lateral Sclerosis, sponsored by Rapa Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT04220190 is a Phase 2 study of Amyotrophic Lateral Sclerosis that is actively recruiting participants, run by Rapa Therapeutics. The registered enrollment target is 41 participants, below the 898-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04220190, a Phase 2 study of Amyotrophic Lateral Sclerosis, is actively recruiting participants, sponsored by Rapa Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).
Conditions Studied
Interventions
- BIOLOGICAL RAPA-501 Autologous T stem cells
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2025-01-02 |
| Est. Completion | 2027-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04220190
The ClinicalTrials.gov registry entry for NCT04220190 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 898-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (95% lower). The listed sponsor is Rapa Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which RAPA-501 Autologous T stem cells is the first listed.
NCT04220190 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04220190 about?
NCT04220190 is a clinical study titled "RAPA-501 Therapy for ALS". RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).
What is the current status of trial NCT04220190?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2025-01-02. Estimated completion is 2027-06-01.
What conditions does trial NCT04220190 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis.
What interventions are being tested in trial NCT04220190?
The interventions under investigation include: RAPA-501 Autologous T stem cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT04220190?
This trial is sponsored by Rapa Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04220190 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
RECRUITING · Phase 2
-
HEALEY ALS Platform Trial - Master Protocol
RECRUITING · Phase 2
-
A Study of Ranolazine in ALS
RECRUITING · Phase 2
-
Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
ACTIVE NOT RECRUITING · Phase 2
-
Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.